cladribine + busulfan + cyclophosphamide

Cladribine + busulfan + cyclophosphamide is a combination chemotherapy regimen used as an intensive conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT), particularly in patients with relapsed or refractory acute myeloid leukemia (AML)[1][2][4]. - **Cladribine** is a purine nucleoside analog that inhibits DNA synthesis and repair, leading to apoptosis in both dividing and resting lymphocytes. It exerts cytotoxic effects on B and T lymphocytes by accumulating intracellularly as cladribine triphosphate, which competes with adenine triphosphate during DNA synthesis[3]. - **Busulfan** is an alkylating agent that crosslinks DNA strands, resulting in cell death. It is commonly used for myeloablation before stem cell transplantation[5]. - **Cyclophosphamide** is another alkylating agent that interferes with DNA replication and transcription through crosslinking of DNA strands. This combination leverages the synergistic anti-leukemic effects of these agents while providing immunosuppression necessary for successful engraftment during allo-HSCT. The regimen has demonstrated favorable efficacy and acceptable toxicity profiles in clinical studies involving patients with relapsed or refractory AML[1][2][4].

Other names

cladribine plus BuCycladribine plus busulfan and cyclophosphamide